FBIO Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 461.8%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 478.3%. Given that Perspective Therapeutics has higher upside potential than Fortress Biotech, analysts believe Perspective Therapeutics is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.853, which suggesting that the stock is 85.291% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Fortress Biotech's net income of -$10.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.70x versus 16.84x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Checkpoint Therapeutics has a net margin of -80.55% compared to Fortress Biotech's net margin of -16268.29%. Fortress Biotech's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 461.8%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 3.42%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

Fortress Biotech has a beta of 1.853, which suggesting that the stock is 85.291% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.179, suggesting its more volatile than the S&P 500 by 17.928%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Fortress Biotech's net income of -$10.6M is higher than Checkpoint Therapeutics's net income of -$11.2M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.70x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Journey Medical has a net margin of -80.55% compared to Fortress Biotech's net margin of -31%. Fortress Biotech's return on equity of -- beat Journey Medical's return on equity of -54.07%.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 461.8%. On the other hand Journey Medical has an analysts' consensus of $9.75 which suggests that it could grow by 39.29%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Fortress Biotech has a beta of 1.853, which suggesting that the stock is 85.291% more volatile than S&P 500. In comparison Journey Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Journey Medical pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are smaller than Journey Medical quarterly revenues of $13.1M. Fortress Biotech's net income of -$10.6M is lower than Journey Medical's net income of -$4.1M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Journey Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.70x versus 2.63x for Journey Medical. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -80.55% compared to Fortress Biotech's net margin of -6391.57%. Fortress Biotech's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 461.8%. On the other hand Janux Therapeutics has an analysts' consensus of $84.12 which suggests that it could grow by 233.55%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

Fortress Biotech has a beta of 1.853, which suggesting that the stock is 85.291% more volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $13.1M, which are larger than Janux Therapeutics quarterly revenues of $439K. Fortress Biotech's net income of -$10.6M is higher than Janux Therapeutics's net income of -$23.5M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.70x versus 110.03x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.